Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 3 studies | 27% ± 4% | |
type I pneumocyte | 3 studies | 21% ± 3% |
Insufficient scRNA-seq data for expression of CYP4Z1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 98% | 609.76 | 448 / 459 | 72% | 136.04 | 801 / 1118 |
lung | 98% | 149.61 | 565 / 578 | 18% | 0.65 | 210 / 1155 |
esophagus | 87% | 63.03 | 1258 / 1445 | 11% | 0.25 | 21 / 183 |
prostate | 93% | 120.69 | 227 / 245 | 5% | 0.13 | 27 / 502 |
adipose | 97% | 180.40 | 1162 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 92% | 67.44 | 1228 / 1335 | 0% | 0 | 0 / 0 |
bladder | 71% | 43.33 | 15 / 21 | 20% | 0.67 | 103 / 504 |
thymus | 78% | 48.35 | 510 / 653 | 3% | 0.06 | 21 / 605 |
brain | 75% | 48.95 | 1977 / 2642 | 1% | 0.01 | 4 / 705 |
muscle | 72% | 35.80 | 576 / 803 | 0% | 0 | 0 / 0 |
heart | 67% | 35.97 | 577 / 861 | 0% | 0 | 0 / 0 |
stomach | 63% | 26.09 | 226 / 359 | 3% | 0.06 | 8 / 286 |
skin | 64% | 58.90 | 1162 / 1809 | 1% | 0.02 | 3 / 472 |
uterus | 36% | 18.03 | 61 / 170 | 28% | 1.37 | 128 / 459 |
liver | 56% | 28.80 | 126 / 226 | 4% | 0.08 | 15 / 406 |
ovary | 7% | 3.41 | 13 / 180 | 52% | 1.88 | 223 / 430 |
tonsil | 0% | 0 | 0 / 0 | 47% | 1.28 | 21 / 45 |
kidney | 40% | 12.60 | 36 / 89 | 2% | 0.03 | 15 / 901 |
intestine | 36% | 16.58 | 345 / 966 | 3% | 0.05 | 14 / 527 |
adrenal gland | 37% | 16.75 | 96 / 258 | 0% | 0.01 | 1 / 230 |
pancreas | 6% | 1.77 | 21 / 328 | 4% | 0.20 | 7 / 178 |
spleen | 1% | 0.29 | 3 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0.09 | 3 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0019369 | Biological process | arachidonic acid metabolic process |
GO_0048252 | Biological process | lauric acid metabolic process |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005506 | Molecular function | iron ion binding |
GO_0008404 | Molecular function | arachidonic acid 14,15-epoxygenase activity |
GO_0020037 | Molecular function | heme binding |
GO_0070330 | Molecular function | aromatase activity |
GO_0052722 | Molecular function | fatty acid in-chain hydroxylase activity |
Gene name | CYP4Z1 |
Protein name | Cytochrome P450 4Z1 (EC 1.14.14.1) (CYPIVZ1) (Laurate 7-monooxygenase) (EC 1.14.14.130) |
Synonyms | UNQ3060/PRO9882 |
Description | FUNCTION: A cytochrome P450 monooxygenase that catalyzes the in-chain oxidation of fatty acids . Catalyzes the hydroxylation of carbon-hydrogen bonds. Hydroxylates lauric and myristic acids predominantly at the omega-4 and omega-2 positions, respectively . Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA). Displays an absolute stereoselectivity in the epoxidation of arachidonic acid producing the 14(S),15(R)-epoxyeicosatrienoic acid (EET) enantiomer . Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) . . |
Accessions | ENST00000334194.4 Q86W10 |